Molecular basis of the selective activity of vitamin D analogues

✍ Scribed by Carsten Carlberg

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 136 KB
• Volume: 88
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/jcb.10337

✦ Synopsis

Abstract

More than 2,000 synthetic analogues of the biological active form of vitamin D, 1α,25‐dihydroxyvitamin D~3~ (1α,25(OH)~2~D~3~), are presently known. Basically, all of them interfere with the molecular switch of nuclear 1α,25(OH)~2~D~3~ signaling, which is the complex of the vitamin D receptor (VDR), the retinoid X receptor (RXR), and a 1α,25(OH)~2~D~3~ response element (VDRE). Central element of this molecular switch is the ligand‐binding domain (LBD) of the VDR, which can be stabilized by a 1α,25(OH)~2~D~3~ analogue either in its agonistic, antagonistic, or non‐agonistic conformation. The positioning of helix 12 of the LBD is of most critical importance for these conformations. In each of the three conformations, the VDR performs different protein–protein interactions, which then result in a characteristic functional profile. Most 1α,25(OH)~2~D~3~ analogues have been identified as agonists, a few are antagonists (e.g., ZK159222 and TEI‐9647), and only Gemini and some of its derivatives act under restricted conditions as non‐agonists. The functional profile of some 1α,25(OH)~2~D~3~ analogues, such as EB1089 and Gemini, can be modulated by protein and DNA interaction partners of the VDR. This provides them with some selectivity for DNA‐dependent and ‐independent signaling pathways and VDRE structures. J. Cell. Biochem. 88: 274–281, 2003. © 2002 Wiley‐Liss, Inc.